MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
Nonsmall cell lung cancer (NSCLC) is the major cause of lung cancer-related deaths in the United States. We are developing cell-based vaccines as a new approach for the treatment of NSCLC. NSCLC is broadly divided into 3 histologic subtypes: adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Since these subtypes are derived from the same progenitor cells, we hypothesized that they share common tumor antigens, and vaccines that induce immune reactivity against 1 subtype may also induce immunity against other subtypes. Our vaccine strategy has focused on activating tumor-specific CD4(+) T cells, a population of lymphocytes that facilitates the optimal activation of effector and memory cytotoxic CD8(+) T cells. We now report that our NSCLC MHC II vaccines prepared from adeno, squamous or large cell carcinomas each activate CD4(+) T cells that cross-react with the other NSCLC subtypes and do not react with HLA-DR-matched normal lung fibroblasts or other HLA-DR-matched nonlung tumor cells. Using MHC II NSCLC vaccines expressing the DR1, DR4, DR7 or DR15 alleles, we also demonstrate that antigens shared among the different subtypes are presented by multiple HLA-DR alleles. Therefore, MHC II NSCLC vaccines expressing a single HLA-DR allele activate NSCLC-specific CD4(+) T cells that react with the 3 major classes of NSCLC, and the antigens recognized by the activated T cells are presented by several common HLA-DR alleles, suggesting that the MHC II NSCLC vaccines are potential immunotherapeutics for a range of NSCLC patients.
Srivastava
Minu K
MK
Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA.
Bosch
Jacobus J
JJ
Wilson
Ashley L
AL
Edelman
Martin J
MJ
Ostrand-Rosenberg
Suzanne
S
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000235:genetics / Q000276:immunology / Q000628:therapy; D000483:Alleles; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D018122:B7-1 Antigen / Q000096:biosynthesis / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D045744:Cell Line, Tumor; D003429:Cross Reactions; D006684:HLA-DR Antigens / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D008213:Lymphocyte Activation; D022423:Myeloid Cells / Q000276:immunology; D014162:Transfection
D000911:Antibodies, Monoclonal; D018122:B7-1 Antigen; D019496:Cancer Vaccines; D006684:HLA-DR Antigens
Cancer Res. 2007 May 1;67(9):4499-506
17483366
Cancer Gene Ther. 2006 Jun;13(6):555-62
16410826
Cancer Immunol Immunother. 2008 Mar;57(3):389-98
17724589
Adv Immunol. 2000;75:159-208
10879284
J Exp Med. 1998 Dec 21;188(12):2357-68
9858522
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Cancer Biol Ther. 2006 Feb;5(2):145-9
16357522
Expert Opin Biol Ther. 2007 Jan;7(1):89-102
17150021
Cancer Immunol Immunother. 2006 Dec;55(12):1553-64
16491401
Clin Cancer Res. 2003 Nov 15;9(15):5559-65
14654536
J Immunol. 2004 Jul 15;173(2):1085-93
15240697
Cancer Immunol Immunother. 2010 Jan;59(1):103-12
19557412
Cancer Res. 2004 Mar 1;64(5):1867-74
14996751
Cancer Immunol Immunother. 2008 Oct;57(10):1493-504
18322683
Cancer Res. 1998 Apr 1;58(7):1486-93
9537252
Nat Immunol. 2004 Sep;5(9):927-33
15300249
Science. 1994 Jul 1;265(5168):106-9
8016643
Clin Cancer Res. 1998 Sep;4(9):2279-89
9748150
Cancer Immunol Immunother. 2000 Apr;49(1):34-45
10782864
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Expert Opin Emerg Drugs. 2006 Sep;11(3):445-59
16939384
Science. 2004 Jul 9;305(5681):200-5
15247469
Nat Rev Immunol. 2009 Mar;9(3):162-74
19197294
J Clin Oncol. 2005 Dec 10;23(35):9022-8
16219932
J Clin Oncol. 2005 Sep 20;23(27):6674-81
16170175
J Immunol. 2009 Apr 15;182(8):4499-506
19342621
Immunol Rev. 1999 Aug;170:101-14
10566145
Cancer Res. 2006 Jan 15;66(2):1147-54
16424052
J Clin Oncol. 2004 Jul 15;22(14):2800-7
15254047
Lung Cancer. 2007 Sep;57(3):365-72
17509725
Immunology. 2007 Feb;120(2):148-59
17274112
Nature. 2003 Feb 20;421(6925):852-6
12594515
J Natl Cancer Inst. 2004 Feb 18;96(4):326-31
14970281
J Exp Med. 1982 Mar 1;155(3):768-82
6801178
J Exp Med. 1997 Jul 7;186(1):65-70
9206998
J Immunol. 2004 Mar 1;172(5):3289-96
14978137
EMBO J. 1996 Jan 15;15(2):418-28
8617217
Cancer Gene Ther. 2003 Nov;10(11):850-8
14605671
J Control Release. 2003 Aug 28;91(1-2):225-31
12932654
Science. 2003 Apr 11;300(5617):337-9
12690201
Nature. 1998 Jun 4;393(6684):480-3
9624005
J Exp Med. 1995 Feb 1;181(2):619-29
7836917